Payment overview · 2025
General Payments
$999.93
57 reported records · 17 companies
Healthcare provider profile · identity verified
Sunitha Chacko Alexander, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · THE WOODLANDS, TX · NPI 1376507210
Verified facts
What the public records show
CMS Open Payments records show Sunitha Chacko Alexander, MD received $999.93 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 26.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.62 | 26.2% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $140.39 | 14.0% | 14 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $80.29 | 8.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.70 | 7.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.01 | 6.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.98 | 5.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$51.23 | 5.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.56 | 4.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.49 | 3.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.78 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.27 | 2.9% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.96 | 2.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.55 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.13 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.06 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.47 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $999.93 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $224.94 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $210.69 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $140.39 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $140.39 | 14 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $80.29 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.98 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.98 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.98 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $51.23 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.68 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 122 |
| Losartan Potassium | Losartan Potassium | 329 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 84 |
| Gabapentin | Gabapentin | 221 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 70 |
| Lisinopril | Lisinopril | 152 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 56 |
| Omeprazole | Omeprazole | 134 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 43 |
| Metformin Hcl | Metformin Hcl | 121 | 42 |
| Furosemide | Furosemide | 119 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 39 |
| Montelukast Sodium | Montelukast Sodium | 112 | 49 |
| Azithromycin | Azithromycin | 111 | 101 |
| Potassium Chloride | Potassium Chloride | 89 | 26 |
| Simvastatin | Simvastatin | 89 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 29 |
| Alendronate Sodium | Alendronate Sodium | 78 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Methylprednisolone | Methylprednisolone | 68 | 61 |
| Carvedilol | Carvedilol | 67 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 23 |
| Eliquis | Apixaban | 62 | 19 |
| Spironolactone | Spironolactone | 62 | 19 |
| Jardiance | Empagliflozin | 61 | 18 |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Glimepiride | Glimepiride | 58 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 48 |
| Clonazepam | Clonazepam | 55 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 41 |
| Nystatin | Nystatin | 53 | 24 |
| Ozempic | Semaglutide | 52 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 25 |
| Tramadol Hcl | Tramadol Hcl | 50 | 23 |
| Atenolol | Atenolol | 49 | 16 |
| Allopurinol | Allopurinol | 48 | 18 |
| Prednisone | Prednisone | 47 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 16 |
| Alprazolam | Alprazolam | 45 | 19 |
| Famotidine | Famotidine | 45 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 34 |
| Fluconazole | Fluconazole | 38 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Valsartan | Valsartan | 36 | 14 |
| Ezetimibe | Ezetimibe | 35 | 13 |
| Nifedipine Er | Nifedipine | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 13 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Trazodone Hcl | Trazodone Hcl | 33 | 13 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 24 |
| Buspirone Hcl | Buspirone Hcl | 30 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 17 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Valacyclovir | Valacyclovir Hcl | 28 | 19 |
| Benazepril Hcl | Benazepril Hcl | 27 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 17 |
| Finasteride | Finasteride | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 16 |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 14 |
| Cefdinir | Cefdinir | 14 | 13 |
| Cephalexin | Cephalexin | 14 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $999.93 · 57 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, Fibroscan, GEMTESA, INSPIRE, JARDIANCE, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, SYMPLICITY G3, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYKAT XR, Veozah, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error